{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:34:56Z","timestamp":1768556096855,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/pr.2017.145","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T16:01:29Z","timestamp":1497369689000},"page":"776-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus"],"prefix":"10.1038","volume":"82","author":[{"given":"Caitlin J","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelli K","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M","family":"Dagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"BFpr2017145_CR1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1542\/peds.2008-0313","volume":"123","author":"JM Dagle","year":"2009","unstructured":"Dagle JM, Lepp NT, Cooper ME et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 2009;123:1116\u201323.","journal-title":"Pediatrics"},{"key":"BFpr2017145_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.semperi.2011.09.019","volume":"36","author":"H Hajj","year":"2012","unstructured":"Hajj H, Dagle JM . Genetics of patent ductus arteriosus susceptibility and treatment. Semin Perinatol 2012;36:98\u2013104.","journal-title":"Semin Perinatol"},{"key":"BFpr2017145_CR3","unstructured":"How Is Patent Ductus Arteriosus Treated? National Heart, Lung, and Blood Institute, 2011. Available at https:\/\/www.nhlbi.nih.gov\/health\/health-topics\/topics\/pda\/treatment ."},{"key":"BFpr2017145_CR4","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0022-3476(83)80022-5","volume":"102","author":"WM Gersony","year":"1983","unstructured":"Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895\u2013906.","journal-title":"J Pediatr"},{"key":"BFpr2017145_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00003246-200202000-00013","volume":"30","author":"CL Shaffer","year":"2002","unstructured":"Shaffer CL, Gal P, Ransom JL et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 2002;30:343\u20138.","journal-title":"Crit Care Med"},{"key":"BFpr2017145_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2125.2004.02139.x","volume":"58","author":"JM Smyth","year":"2004","unstructured":"Smyth JM, Collier PS, Darwish M et al. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. Br J Clin Pharmacol 2004;58:249\u201358.","journal-title":"Br J Clin Pharmacol"},{"key":"BFpr2017145_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1542\/peds.2007-2313","volume":"122","author":"PM Lavoie","year":"2008","unstructured":"Lavoie PM, Pham C, Jang KL . Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics 2008;122:479\u201385.","journal-title":"Pediatrics"},{"key":"BFpr2017145_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","volume":"37","author":"UA Meyer","year":"1997","unstructured":"Meyer UA, Zanger UM . Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269\u201396.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFpr2017145_CR9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","volume":"20","author":"D Van Booven","year":"2010","unstructured":"Van Booven D, Marsh S, McLeod H et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010;20:277\u201381.","journal-title":"Pharmacogenet Genomics"},{"key":"BFpr2017145_CR10","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.2174\/092986709789057635","volume":"16","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Zhou ZW, Yang LP, Cai JP . Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009;16:3480\u2013675.","journal-title":"Curr Med Chem"},{"key":"BFpr2017145_CR11","first-page":"108","volume":"12","author":"ZK Ali","year":"2009","unstructured":"Ali ZK, Kim RJ, Ysla FM . CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Discov Dev 2009;12:108\u201314.","journal-title":"Curr Opin Drug Discov Dev"},{"key":"BFpr2017145_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263\u20135.","journal-title":"Bioinformatics"},{"key":"BFpr2017145_CR13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/ng1669","volume":"37","author":"PI de Bakker","year":"2005","unstructured":"de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D . Efficiency and power in genetic association studies. Nat Genet 2005;37:1217\u201323.","journal-title":"Nat Genet"},{"key":"BFpr2017145_CR14","first-page":"506","volume":"52","author":"RS Spielman","year":"1993","unstructured":"Spielman RS, McGinnis RE, Ewens WJ . Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506\u201316.","journal-title":"Am J Hum Genet"},{"key":"BFpr2017145_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00439-006-0260-8","volume":"121","author":"M Wadelius","year":"2007","unstructured":"Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23\u201334.","journal-title":"Hum Genet"},{"key":"BFpr2017145_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/00008571-200412000-00004","volume":"14","author":"BP King","year":"2004","unstructured":"King BP, Khan TI, Aithal GP, Kamali F, Daly AK . Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004;14:813\u201322.","journal-title":"Pharmacogenetics"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pr2017145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr2017145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pr.2017.145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pr2017145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:45Z","timestamp":1684616565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pr2017145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFpr2017145"],"URL":"https:\/\/doi.org\/10.1038\/pr.2017.145","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]},"assertion":[{"value":"3 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}